Synta Pharmaceuticals Corp. (SNTA) was a big mover last session, as the company saw its shares rise by over 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company, as the stock is now down over 28% in the past one-month time frame.
This biopharmaceutical company has seen 1 negative revision in the past one month, while two estimates moved north. However, its Zacks Consensus Estimate moved lower over the same period, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher can last.
Synta Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Investors interested in the med-biomed industry may consider stocks like AMAG Pharmaceuticals, Inc. (AMAG), Heska Corporation (HSKA) and Gilead Sciences Inc. (GILD). While AMAG Pharmaceuticals and Heska Corporation hold a Zacks Rank #1 (Strong Buy), Gilead Sciences carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
SYNTA PHARMACEUTICALS INC (SNTA): Free Stock Analysis Report
AMAG PHARMACEUTICALS INC (AMAG): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
GILEAD SCIENCES INC (GILD): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Personal Investing Ideas & Strategies